159 related articles for article (PubMed ID: 26120010)
1. Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects.
Patel G; King A; Dutta S; Korb S; Wade JR; Foulds P; Sumeray M
J Clin Pharmacol; 2016 Jan; 56(1):47-55. PubMed ID: 26120010
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia.
Tuteja S; Duffy D; Dunbar RL; Movva R; Gadi R; Bloedon LT; Cuchel M
Pharmacotherapy; 2014 Mar; 34(3):227-39. PubMed ID: 24734312
[TBL] [Abstract][Full Text] [Related]
3. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females.
Trapnell CB; Connolly M; Pentikis H; Forbes WP; Bettenhausen DK
Ann Pharmacother; 2007 Feb; 41(2):222-8. PubMed ID: 17284510
[TBL] [Abstract][Full Text] [Related]
4. Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
Bifano M; Sevinsky H; Hwang C; Kandoussi H; Jiang H; Grasela D; Bertz R
Antivir Ther; 2014; 19(5):511-9. PubMed ID: 24343001
[TBL] [Abstract][Full Text] [Related]
5. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney BP; Mathias A
Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
[TBL] [Abstract][Full Text] [Related]
6. Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.
Schmitt-Hoffmann AH; Roos B; Sauer J; Schleimer M; Schoetzau A; Leese PT; Weidekamm E; Maares J
Clin Exp Dermatol; 2011 Apr; 36 Suppl 2():4-11. PubMed ID: 21443598
[TBL] [Abstract][Full Text] [Related]
7. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.
German P; Moorehead L; Pang P; Vimal M; Mathias A
J Clin Pharmacol; 2014 Nov; 54(11):1290-8. PubMed ID: 24925712
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
[TBL] [Abstract][Full Text] [Related]
9. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
10. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.
Zhang J; Chung E; Yones C; Persson A; Mahnke L; Eley T; Xu X; Bertz R
Antivir Ther; 2011; 16(2):157-64. PubMed ID: 21447864
[TBL] [Abstract][Full Text] [Related]
11. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
Perry CM
Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
[TBL] [Abstract][Full Text] [Related]
12. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
[TBL] [Abstract][Full Text] [Related]
13. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects and efficacy of a triphasic oral contraceptive (norgestimate/ethinyl estradiol).
Andolsek KM; Burkman RT; Kafrissen ME; Olson W; Osterman J
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():122-5. PubMed ID: 8260970
[No Abstract] [Full Text] [Related]
15. Long-term profile of a new progestin.
Lippman J
Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
[TBL] [Abstract][Full Text] [Related]
16. Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.
Anderson MS; Hanley WD; Moreau AR; Jin B; Bieberdorf FA; Kost JT; Wenning LA; Stone JA; Wagner JA; Iwamoto M
Br J Clin Pharmacol; 2011 Apr; 71(4):616-20. PubMed ID: 21395656
[TBL] [Abstract][Full Text] [Related]
17. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.
Davis KA; Miyares MA
Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
[TBL] [Abstract][Full Text] [Related]
19. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
20. Experience with a new low dose oral contraceptive: norgestimate & ethinyl estradiol.
Rubio-Lotvin B; Gonzales-Ansorena R
Acta Eur Fertil; 1978 Mar; 9(1):1-6. PubMed ID: 696184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]